Article
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jun 2007
Di Leo A, Tanner M, Desmedt C, Paesmans M, Cardoso F, Durbecq V, Chan S, Perren T, Aapro M, Sotiriou C, Piccart M J, Larsimont D, Isola J
Abstract excerpt
BACKGROUND: Preclinical data indicate that p-53 gene mutations predict resistance to doxorubicin (A) but not to docetaxel (Taxotere) (T). In the TAX 303 trial, A and T have been compared with advanced breast cancer patients. PATIENTS AND METHODS: Primary tumor samples from patients participating in the TAX 303 trial were collected. p-53 gene mutations were evaluated by denaturing high-performance liquid...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.